Treatment with STI571, a tyrosine kinase ihibitor, for gastrointestinal stromal tumor with peritoneal dissemination and multiple liver metastases

Journal of Gastroenterology

Volumn 38, Issue 9, 2003, Pages 896-899

  Yamamoto, Satoshi ^a   Kubo, Shoji ^a   Shuto, Taichi ^a   Yamamoto, Takatsugu ^a   Hirohashi, Kazuhiro ^a   Tanaka, Hiromu ^a   Takemura, Shigekazu ^a   Kanazawa, Akishige ^a   Kinoshita, Hiroaki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastrointestinal stromal tumor; Position emission tomography; Tyrosine kinase inhibitor

Indexed keywords

ALCOHOL; CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TEGAFUR; UFT;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; MICROWAVE IRRADIATION; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SMALL INTESTINE RESECTION;

ADULT; ENZYME INHIBITORS; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM INVASIVENESS; NEOPLASMS, CONNECTIVE TISSUE; PERITONEUM; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 0142211283     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-002-1168-2     Document Type: Article

References (10)

1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-20.
2. Sarloma-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD 117: a sensitive marker for gastrointestinal stomal tumors that is more specific than CD 34. Mod Pathol 1998;11:728-34.
3. Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, et al. Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990;63:213-4.
4. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of C-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
5. Lux ML, Rubin BP, Biase TL, Chen C-J, Maclure T, Demetri G, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-5.
6. Plaat BE, Hollema H, Molenaar WM, Torn Broers GH, Pijpe J, Mastik MF, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumours: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000;18:3211-20.
7. Van Giabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcomas: an analysis of 2185 patients treated with anthracycline-containing first-line regimens. A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999;17:150-7.
8. Dematteo RP, Heinrich MC, El-Rifal WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466-77.
9. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. New Engl J Med 2001;344:1052-6.
10. Van Oosterom AT, Judson I, Verweij J, Stroobants S, di Paola ED, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.